SeaStar Medical Holding Corp Stock Price, News & Analysis

SeaStar Medical (NASDAQ: ICU) has announced a $4 million registered direct offering priced at-the-market under Nasdaq rules. The company will issue 5,242,464 shares of common stock at $0.763 per share.

Additionally, in a concurrent private placement, SeaStar Medical will issue unregistered warrants to purchase up to 5,242,464 shares with an exercise price of $0.638 per share. The warrants will be exercisable immediately and expire in five years. H.C. Wainwright & Co. serves as the exclusive placement agent, with the offering expected to close around July 10, 2025.

The company plans to use the net proceeds for general corporate purposes, including working capital and capital expenditures.

SeaStar Medical (NASDAQ: ICU) announced that Texas Children's Hospital has adopted its QUELIMMUNE therapy for treating pediatric patients with Acute Kidney Injury (AKI). The therapy, FDA-approved in 2024 under a Humanitarian Device Exemption, has shown remarkable results with a 77% survival rate compared to standard care, representing a 50% reduction in mortality.

The Selective Cytopheretic Device (SCD) therapy works by neutralizing over-active immune cells and stopping cytokine storms in critically ill patients. Clinical data showed no dialysis requirement for survivors at Day 60 post-ICU discharge. The company is currently conducting the NEUTRALIZE-AKI pivotal trial in 200 adults and has received FDA Breakthrough Device Designation for six different indications.

SeaStar Medical (NASDAQ:ICU) has successfully met Nasdaq's minimum stockholders' equity requirement of $2.5 million and all other criteria for continued listing on The Nasdaq Capital Market, resolving its previous listing concerns.

CEO Eric Schloff emphasized that the company can now focus on commercializing QUELIMMUNE and advancing their clinical development of the Selective Cytopheretic Device (SCD) therapy in the NEUTRALIZE-AKI pivotal trial for adult patients with Acute Kidney Injury receiving continuous renal replacement therapy.

SeaStar Medical (NASDAQ: ICU) has undertaken several measures to regain compliance with Nasdaq's listing requirements after receiving a notification of non-compliance in June 2024. The company completed a $4.0 million public offering and secured a $15.0 million purchase agreement with Lincoln Park Capital.

The company has expanded its customer base to six facilities for QUELIMMUNE, its FDA-approved product for pediatric patients with multiple organ failure, which has shown to reduce mortality by approximately 50%. Additionally, SeaStar implemented cost-cutting measures and restructured approximately $1.2 million in employee compensation liabilities. The company believes these actions have helped it meet the $2.5 million stockholders' equity requirement for continued Nasdaq listing, pending formal confirmation.

SeaStar Medical (NASDAQ: ICU) announced a two-part video series featuring their QUELIMMUNE therapy at Cincinnati Children's Hospital Medical Center. The first video, available June 24, 2025, features Dr. Stuart Goldstein and CMO Dr. Kevin Chung discussing QUELIMMUNE's potential to reduce destructive hyperinflammation in organ failure cases.

The second video, releasing June 26, 2025, showcases a patient testimonial from Kurt and his father, describing Kurt's rapid recovery from post-heart surgery complications using QUELIMMUNE therapy. Both videos will be accessible through SeaStar Medical's investor relations website.

SeaStar Medical (NASDAQ: ICU) has announced a public offering to raise up to $8 million, with $4 million expected initially and potential additional $4 million through warrant exercises. The offering includes 6,153,847 shares of common stock priced at $0.65 per share, along with Series A warrants (5-year term) and Series B short-term warrants (18-month term), both with $0.65 exercise price. The offering, managed by H.C. Wainwright & Co. as exclusive placement agent, is expected to close around June 23, 2025. The company plans to use proceeds for general corporate purposes. The offering is made through a Form S-1 registration statement declared effective on June 20, 2025.

SeaStar Medical (Nasdaq: ICU) and AREVA Research Institute announced a significant Department of Defense (DoD) grant award to study SeaStar's Selective Cytopheretic Device (SCD) therapy. The $2 million grant, selected from 160 submissions to the Military Burn Research Program, will fund a three-year study starting July 2025 to evaluate SCD therapy's effectiveness in reducing hyperinflammation in cases of severe burns, inhalation injury, and sepsis. The SCD therapy, used alongside continuous renal replacement therapy (CRRT), aims to neutralize hyperinflammation and support organ recovery. The research will be conducted at AREVA Institute in San Antonio, with operational support from The Geneva Foundation, potentially advancing treatment options for both military and civilian trauma patients.

SeaStar Medical (NASDAQ: ICU) has secured CMS coverage for Medicare and Medicaid patients enrolled in the NEUTRALIZE-CRS clinical trial, marking its second CMS reimbursement award. The trial evaluates the company's Selective Cytopheretic Device (SCD) therapy in patients with cardiorenal syndrome awaiting LVAD implantation. This rare achievement, granted to less than 100 trials annually, follows their July 2024 CMS coverage for the NEUTRALIZE-AKI pivotal trial. The company is also advancing pre-commercialization efforts for SCD therapy in Acute Kidney Injury (AKI) patients, with the NEUTRALIZE-AKI trial currently 50% enrolled. Both the AKI and cardiorenal syndrome applications have received FDA Breakthrough Device Designation. The NEUTRALIZE-CRS trial, supported by a $3.6M NIH grant, aims to enroll 20 patients across five clinical sites.

SeaStar Medical (NASDAQ: ICU) reported Q1 2025 financial results, highlighting a four-fold increase in QUELIMMUNE net product revenue to $293,000 compared to Q4 2024's $68,000. The company's NEUTRALIZE-AKI pivotal trial reached 50% enrollment, triggering an interim analysis expected in Q3 2025. SeaStar secured three new customers for QUELIMMUNE and received two new FDA Breakthrough Device Designations for SCD therapy in cardiac surgery patients. Financial results showed a net loss of $3.8 million ($0.44 per share), improved from $12.7 million loss in Q1 2024. R&D expenses increased to $2.4 million, while G&A expenses decreased to $1.7 million. The company reported cash and equivalents of $5.3 million, bolstered by a $6.0 million registered direct offering in January 2025.